9.2 PROTOCOL REVIEW AND MONITORING SYSTEM Purpose The Scientific Review Committee (SRC) ensures that all cancer clinical trials conducted under the auspices of Vanderbilt-lngram Cancer Center (VICC) meet the committee's pre-defined standards of scientific design. The Committee is also responsible for assigning a priority score for each protocol that indicates the amount of Cancer Center support a particular protocol should receive. Protocols requiring full committee review are evaluated for appropriate scientific rationale, clearly defined specific aims, achievable study endpoints, a plausible biostatistical plan, feasibility issues, and a justifiable ability to accrue patients. These criteria exist to ensure that the study is conducted in accordance with scientific principles that will allow the scientific aims of the study to be met. This clearly sets the SRC's role apart from the IRB, which primarily concerned with patient safety, while the SRC is focused on sound science designed one day to be translated into better practice. While the SRC and IRB have separate and distinct functions, they complement each other by ensuring the overall integrity of the study from both scientific and patient protection viewpoints. The SRC also assists in determining the level of VICC support for a particular protocol;the IRB has no role in this determination.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-15
Application #
8327673
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
15
Fiscal Year
2011
Total Cost
$84,984
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Marks, Christian R; Shonesy, Brian C; Wang, Xiaohan et al. (2018) Activated CaMKII? Binds to the mGlu5 Metabotropic Glutamate Receptor and Modulates Calcium Mobilization. Mol Pharmacol 94:1352-1362
Singh, Kshipra; Coburn, Lori A; Asim, Mohammad et al. (2018) Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses. Cancer Res 78:4303-4315
Pollins, Alonda C; Boyer, Richard B; Nussenbaum, Marlieke et al. (2018) Comparing Processed Nerve Allografts and Assessing Their Capacity to Retain and Release Nerve Growth Factor. Ann Plast Surg 81:198-202
Coppola, Jennifer J; Disney, Anita A (2018) Most calbindin-immunoreactive neurons, but few calretinin-immunoreactive neurons, express the m1 acetylcholine receptor in the middle temporal visual area of the macaque monkey. Brain Behav 8:e01071
Hull, P C; Buchowski, M; Canedo, J R et al. (2018) Childhood obesity prevention cluster randomized trial for Hispanic families: outcomes of the healthy families study. Pediatr Obes 13:686-696
Fensterheim, Benjamin A; Young, Jamey D; Luan, Liming et al. (2018) The TLR4 Agonist Monophosphoryl Lipid A Drives Broad Resistance to Infection via Dynamic Reprogramming of Macrophage Metabolism. J Immunol 200:3777-3789
Covington, Brett C; Spraggins, Jeffrey M; Ynigez-Gutierrez, Audrey E et al. (2018) Response of Hypogean Actinobacterial Genera Secondary Metabolism to Chemical and Biological Stimuli. Appl Environ Microbiol :
Hong, Jun; Maacha, Selma; Belkhiri, Abbes (2018) Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma. Mol Oncol 12:2191-2208
Dahlman, Kimberly Brown; Weinger, Matthew B; Lomis, Kimberly D et al. (2018) Integrating Foundational Sciences in a Clinical Context in the Post-Clerkship Curriculum. Med Sci Educ 28:145-154
Ramsey, Haley E; Fischer, Melissa A; Lee, Taekyu et al. (2018) A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov 8:1566-1581

Showing the most recent 10 out of 2462 publications